反芻動物疫苗市場 - 全球產業規模、佔有率、趨勢、機會及預測（按動物類型、疫苗類型、疫苗適應症、給藥途徑、地區和競爭格局分類，2021-2031年）

全球反芻動物疫苗市場預計將從 2025 年的 39.1 億美元成長到 2031 年的 53.2 億美元，複合年成長率為 5.27%。

這些生物製藥旨在誘導綿羊、山羊和牛等草食性哺乳動物產生適應性免疫，作為抵抗感染疾病的主要防線。該行業的主要驅動力是全球對動物性蛋白質日益成長的需求，這要求畜牧業的健康和生產力達到高標準，以確保糧食安全。此外，各國政府嚴格的跨境疾病根除計畫以及對遏制通用感染疾病傳播的日益重視，也是市場接受度的重要支柱。這些促進因素獨立於技術變革而存在，從而在現代畜牧管理中催生了對全面免疫策略的根本且不可或缺的需求。

然而，市場面臨著許多障礙，因為新型疫苗的商業化規模化生產需要大量的資金投入和監管負擔。應對病毒變異株所需的複雜研究也需要巨額資金，這往往阻礙了小規模的企業進入市場。 AnimalhealthEurope的報告凸顯了這種資本密集的特點：2023年，動物用藥品產業將約8%的總銷售額用於研發。這種高成本結構常常導致新產品上市延遲，並可能阻礙對價格敏感的發展中地區的市場成長。

市場促進因素

全球反芻動物疫苗市場的主要驅動力是全球對乳製品和動物性蛋白質需求的不斷成長。隨著新興經濟體都市化的推進和可支配收入的增加，人們的飲食結構發生改變，畜牧養殖戶正增加生產力以滿足不斷成長的牛肉、牛奶和羊肉消費需求。這種擴張需要嚴格的畜群健康管理，而疫苗接種已成為降低死亡率和最佳化生產效率的重要預防措施。保障糧食供應的經濟壓力迫使養殖戶實施針對地方性病原體和新發病原體的預防性免疫策略，以維持穩定的生產。例如，經合組織-糧農組織於2024年7月發布的《2024-2033年農業展望》預測，到2033年，全球羊肉消費量將增加16%，凸顯了永續畜群擴張和健康維護的必要性。

同時，跨境和通用感染疾病的日益頻繁加速了先進免疫療法的迫切應用。嚴重感染疾病（如口蹄疫和藍舌病）的爆發威脅畜牧業資產並擾亂國際貿易，迫使各國政府實施嚴格的疫苗接種強制措施。氣候變遷進一步加劇了這些風險，促進了病媒的傳播，因此需要迅速採取藥物干預措施來阻止病毒傳播。例如，2024年9月，英國環境、食品和農村事務部宣布，英國確診的藍舌病毒（BTV-3）病例已達82例，顯示疾病管制措施迫在眉睫。這種不穩定的疾病情況支撐著該行業的財務表現。 2024年2月，碩騰公司宣布其2023會計年度畜牧業業務的營業收入成長了6%，這顯示該公司持續依賴獸醫保護措施。

市場挑戰

全球反芻動物疫苗市場的發展受到疫苗研發高額資金需求和嚴格法規環境的顯著限制。開發針對不斷演變的病毒株的有效疫苗需要耗費大量時間和金錢進行廣泛的研究。這種高准入門檻尤其影響那些擁有創新平台但缺乏資金進行漫長臨床試驗和核准流程的中小型生物技術公司。因此，市場日益集中於少數主要企業，削弱了通常推動快速創新和降低價格的競爭壓力。

這種沉重的經濟負擔直接限制了對成本敏感的市場中價格適中的疫苗供應。將單一產品推向市場所需的巨額投資迫使製造商將重點放在高利潤地區，往往忽略了反芻動物健康對其生計至關重要的開發中國家。例如，根據歐洲動物健康協會（AnimalhealthEurope）的數據顯示，2024年獸醫保健產業在研發方面的投資超過6.49億美元。這些巨額的營運成本延緩了新疫苗的商業化進程，限制了該行業快速應對新出現的跨境疾病的能力，並造成了阻礙其拓展全球市場的瓶頸。

市場趨勢

市場正在加速採用mRNA和DNA疫苗平台，與傳統免疫療法相比，這些平台具有更高的速度和柔軟性。這項技術進步使製造商能夠快速設計非複製型抗原來對抗新出現的病毒株，同時避免生產去活化疫苗或減毒活病毒疫苗所需的漫長前置作業時間。這些平台對於控制威脅貿易連續性和牲畜群穩定的重大疫情至關重要。例如，2024年8月，美國農業部（USDA）核准了首個針對H5N1病毒的非活性、非複製型牛疫苗的田間試驗，這標誌著先進生物技術在反芻動物健康管理應用方面邁出了重要一步。

同時，在全球對抗菌素抗藥性（AMR）日益關注的背景下，畜牧業正致力於將疫苗深度融入抗生素減量策略。監管機構和供應鏈相關人員敦促畜牧生產者從被動的抗菌治療轉向預防性免疫通訊協定，從根本上重塑畜群健康管理。這項策略轉變旨在減少重要藥物的整體使用量，同時確保動物福利和生產力。為了支持這些預防措施的成功，英國獸藥協會在其2024年11月發布的《英國獸醫抗生素抗藥性策略2023》（UK-VARSS 2023）文件中指出，2023年肉類用動物高優先級抗生素（HP-CIA）的銷售量已降至0.11毫克/公斤。這反映出人們越來越依賴疫苗接種來抑制對抗生素的依賴。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球反芻動物疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依動物種類（牛、羊和山羊）
  • 依疫苗類型（減毒活病毒疫苗、不活化疫苗、其他）
  • 疫苗適應症（牛病毒性腹瀉感染疾病、牛呼吸道疾病、鉤端螺旋體病、梭狀菌感染、腹瀉/牛腹瀉、口蹄疫、其他）
  • 給藥途徑（注射、鼻腔給藥）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美反芻動物疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲反芻動物疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區反芻動物疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲反芻動物疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美反芻動物疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球反芻動物疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Boehringer Ingelheim International GmbH
• Zoetis Services LLC
• Vaxxinova International BV
• Merck & Co., Inc.
• Bimeda Animal Health Ltd.
• Indian Immunologicals Ltd.
• Elanco Animal Health Incorporated
• Virbac
• Ceva Sante Animale
• CZ Vaccines SAU

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Ruminant Vaccines Market is projected to expand from a valuation of USD 3.91 Billion in 2025 to USD 5.32 Billion by 2031, achieving a CAGR of 5.27%. These biological formulations are designed to induce acquired immunity in herbivorous mammals, such as sheep, goats, and cattle, serving as a primary defense against infectious diseases. The industry is chiefly driven by the growing global requirement for animal-based protein, which demands elevated standards of herd health and productivity to maintain food security. Furthermore, strictly enforced government eradication schemes for transboundary diseases and a sharpened focus on curbing zoonotic transmission act as foundational pillars for market adoption. These drivers operate independently of technological shifts, creating a fundamental baseline need for comprehensive immunization strategies in modern livestock operations.

Conversely, the market encounters substantial obstacles stemming from the heavy capital and regulatory loads required to scale new inoculants commercially. The intricate research necessary to tackle mutating viral strains demands vast financial resources, which often bars entry for smaller organizations. Highlighting this financial intensity, AnimalhealthEurope reported that in 2023, the animal health sector allocated roughly 8% of its total turnover to research and development. This elevated cost structure frequently delays the introduction of novel products, potentially hindering market growth in price-sensitive developing regions.

Market Driver

A primary engine for the Global Ruminant Vaccines Market is the escalating worldwide demand for dairy products and animal-derived protein. As urbanization and rising disposable incomes in emerging economies prompt dietary changes, livestock producers are intensifying operations to satisfy the growing consumption of beef, milk, and sheep meat. This production ramp-up necessitates stringent herd health management, making vaccination a vital preventive tool to reduce mortality rates and optimize efficiency. Economic imperatives to guarantee food supplies force farmers to implement prophylactic immunization strategies against both endemic and novel pathogens to ensure consistent output. For example, the OECD-FAO Agricultural Outlook 2024-2033, published in July 2024, forecasts a 16% rise in global sheep meat consumption by 2033, highlighting the need for sustained herd expansion and health maintenance.

At the same time, the increasing frequency of transboundary and zoonotic animal diseases is accelerating the urgent adoption of advanced immunotherapeutics. Outbreaks of severe viral infections like Foot and Mouth Disease (FMD) and Bluetongue threaten livestock assets and disrupt international trade, compelling governments to impose strict vaccination mandates. Climate variations further facilitate vector spread, heightening these risks and requiring swift pharmaceutical interventions to halt viral transmission. For instance, the Department for Environment, Food & Rural Affairs noted in September 2024 that confirmed Bluetongue virus (BTV-3) cases in the UK's current outbreak hit 82, indicating a critical need for disease control measures. This volatile disease landscape supports financial performance in the sector; Zoetis announced in February 2024 that its livestock portfolio saw 6% operational revenue growth in fiscal 2023, demonstrating the persistent dependence on veterinary safeguards.

Market Challenge

The progression of the Global Ruminant Vaccines Market is notably constrained by high capital requirements and rigorous regulatory environments linked to vaccine development. Formulating effective immunizations for evolving viral strains requires extensive research pathways that deplete significant time and financial resources. This steep barrier to entry disproportionately affects smaller biotechnology firms, which may possess innovative platforms but lack the funding to navigate prolonged clinical trials and approval processes. Consequently, the market sees a consolidation of influence among a few major entities, diminishing the competitive pressures that typically spur rapid innovation and price reductions.

This financial burden directly curtails the availability of affordable vaccines in cost-conscious markets. The massive investment needed to launch a single product compels manufacturers to focus on high-margin regions, often overlooking developing nations where ruminant health is essential for subsistence. Demonstrating the magnitude of these costs, AnimalhealthEurope stated that in 2024, the animal medicines industry invested over USD 649 million in research and development. Such immense overheads slow the commercialization of novel vaccines and restrict the industry's capacity to react quickly to emerging transboundary diseases, creating a bottleneck that stifles broader global market expansion.

Market Trends

The market is increasingly characterized by the accelerated uptake of mRNA and DNA vaccine platforms, which offer greater speed and flexibility compared to traditional immunologics. This technological evolution enables manufacturers to rapidly engineer non-replicating antigens to fight novel viral strains, avoiding the long lead times associated with inactivated or live-attenuated vaccine production. Such platforms are becoming essential for managing high-consequence outbreaks that threaten trade continuity and herd stability. Exemplifying this innovation, the U.S. Department of Agriculture (USDA) authorized the first field trial of a nonviable, non-replicating vaccine for cattle against the H5N1 virus in August 2024, marking a key milestone in applying advanced biotechnologies to ruminant health.

Concurrently, the industry is witnessing the robust integration of vaccines into antibiotic-reduction strategies, driven by intensifying global scrutiny over antimicrobial resistance (AMR). Regulatory bodies and supply chain stakeholders are compelling livestock producers to shift from reactive antibiotic treatments to proactive immunization protocols, fundamentally reshaping herd health management. This strategic pivot aims to lower the aggregate use of medically important drugs while safeguarding animal welfare and productivity. Underscoring the success of these preventive measures, the UK Veterinary Medicines Directorate reported in November 2024, within its 'UK-VARSS 2023' document, that sales of Highest Priority Critically Important Antibiotics (HP-CIAs) in food-producing animals dropped to 0.11 mg/kg in 2023, reflecting the sector's growing reliance on vaccination to curb antimicrobial dependency.

Key Market Players

• Boehringer Ingelheim International GmbH
• Zoetis Services LLC
• Vaxxinova International BV
• Merck & Co., Inc.
• Bimeda Animal Health Ltd.
• Indian Immunologicals Ltd.
• Elanco Animal Health Incorporated
• Virbac
• Ceva Sante Animale
• CZ Vaccines S.A.U.

Report Scope

In this report, the Global Ruminant Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ruminant Vaccines Market, By Animal Type

• Cattle
• Sheep & Goats

Ruminant Vaccines Market, By Vaccine Type

• Modified/ Attenuated Live
• Inactivated (Killed)
• Others

Ruminant Vaccines Market, By Vaccines Indication

• BVD Infection
• Bovine Respiratory Diseases (BRD)
• Leptospirosis
• Clostridial diseases
• Diarrhea/ Scours
• FMD
• Others

Ruminant Vaccines Market, By Route of Administration

• Injectable
• Intranasal

Ruminant Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ruminant Vaccines Market.

Available Customizations:

Global Ruminant Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ruminant Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Cattle, Sheep & Goats)
  • 5.2.2. By Vaccine Type (Modified/ Attenuated Live, Inactivated (Killed), Others)
  • 5.2.3. By Vaccines Indication (BVD Infection, Bovine Respiratory Diseases (BRD), Leptospirosis, Clostridial diseases, Diarrhea/ Scours, FMD, Others)
  • 5.2.4. By Route of Administration (Injectable, Intranasal)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Ruminant Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Vaccine Type
  • 6.2.3. By Vaccines Indication
  • 6.2.4. By Route of Administration
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Ruminant Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Vaccine Type
      • 6.3.1.2.3. By Vaccines Indication
      • 6.3.1.2.4. By Route of Administration
  • 6.3.2. Canada Ruminant Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Vaccine Type
      • 6.3.2.2.3. By Vaccines Indication
      • 6.3.2.2.4. By Route of Administration
  • 6.3.3. Mexico Ruminant Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Vaccine Type
      • 6.3.3.2.3. By Vaccines Indication
      • 6.3.3.2.4. By Route of Administration

7. Europe Ruminant Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Vaccine Type
  • 7.2.3. By Vaccines Indication
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Ruminant Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Vaccine Type
      • 7.3.1.2.3. By Vaccines Indication
      • 7.3.1.2.4. By Route of Administration
  • 7.3.2. France Ruminant Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Vaccine Type
      • 7.3.2.2.3. By Vaccines Indication
      • 7.3.2.2.4. By Route of Administration
  • 7.3.3. United Kingdom Ruminant Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Vaccine Type
      • 7.3.3.2.3. By Vaccines Indication
      • 7.3.3.2.4. By Route of Administration
  • 7.3.4. Italy Ruminant Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Vaccine Type
      • 7.3.4.2.3. By Vaccines Indication
      • 7.3.4.2.4. By Route of Administration
  • 7.3.5. Spain Ruminant Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Vaccine Type
      • 7.3.5.2.3. By Vaccines Indication
      • 7.3.5.2.4. By Route of Administration

8. Asia Pacific Ruminant Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Vaccine Type
  • 8.2.3. By Vaccines Indication
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Ruminant Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Vaccine Type
      • 8.3.1.2.3. By Vaccines Indication
      • 8.3.1.2.4. By Route of Administration
  • 8.3.2. India Ruminant Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Vaccine Type
      • 8.3.2.2.3. By Vaccines Indication
      • 8.3.2.2.4. By Route of Administration
  • 8.3.3. Japan Ruminant Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Vaccine Type
      • 8.3.3.2.3. By Vaccines Indication
      • 8.3.3.2.4. By Route of Administration
  • 8.3.4. South Korea Ruminant Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Vaccine Type
      • 8.3.4.2.3. By Vaccines Indication
      • 8.3.4.2.4. By Route of Administration
  • 8.3.5. Australia Ruminant Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Vaccine Type
      • 8.3.5.2.3. By Vaccines Indication
      • 8.3.5.2.4. By Route of Administration

9. Middle East & Africa Ruminant Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Vaccine Type
  • 9.2.3. By Vaccines Indication
  • 9.2.4. By Route of Administration
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Ruminant Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Vaccine Type
      • 9.3.1.2.3. By Vaccines Indication
      • 9.3.1.2.4. By Route of Administration
  • 9.3.2. UAE Ruminant Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Vaccine Type
      • 9.3.2.2.3. By Vaccines Indication
      • 9.3.2.2.4. By Route of Administration
  • 9.3.3. South Africa Ruminant Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Vaccine Type
      • 9.3.3.2.3. By Vaccines Indication
      • 9.3.3.2.4. By Route of Administration

10. South America Ruminant Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Vaccine Type
  • 10.2.3. By Vaccines Indication
  • 10.2.4. By Route of Administration
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Ruminant Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Vaccine Type
      • 10.3.1.2.3. By Vaccines Indication
      • 10.3.1.2.4. By Route of Administration
  • 10.3.2. Colombia Ruminant Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Vaccine Type
      • 10.3.2.2.3. By Vaccines Indication
      • 10.3.2.2.4. By Route of Administration
  • 10.3.3. Argentina Ruminant Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Vaccine Type
      • 10.3.3.2.3. By Vaccines Indication
      • 10.3.3.2.4. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Ruminant Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boehringer Ingelheim International GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Zoetis Services LLC
• 15.3. Vaxxinova International BV
• 15.4. Merck & Co., Inc.
• 15.5. Bimeda Animal Health Ltd.
• 15.6. Indian Immunologicals Ltd.
• 15.7. Elanco Animal Health Incorporated
• 15.8. Virbac
• 15.9. Ceva Sante Animale
• 15.10. CZ Vaccines S.A.U.

16. Strategic Recommendations

17. About Us & Disclaimer